TW200526197A - Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors - Google Patents

Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors Download PDF

Info

Publication number
TW200526197A
TW200526197A TW093127197A TW93127197A TW200526197A TW 200526197 A TW200526197 A TW 200526197A TW 093127197 A TW093127197 A TW 093127197A TW 93127197 A TW93127197 A TW 93127197A TW 200526197 A TW200526197 A TW 200526197A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
halogen
depression
substituted
Prior art date
Application number
TW093127197A
Other languages
English (en)
Chinese (zh)
Inventor
Megan Ann Gibbs
Earl Laux Giller Jr
Gerard Joseph Marek
Robert Clyde Marshall
Tatiana Stanislavovna Ramey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/769,018 external-priority patent/US20050014848A1/en
Priority claimed from US10/860,721 external-priority patent/US20050009927A1/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200526197A publication Critical patent/TW200526197A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093127197A 2003-09-09 2004-09-08 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors TW200526197A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50127503P 2003-09-09 2003-09-09
US53889804P 2004-01-23 2004-01-23
US54069604P 2004-01-30 2004-01-30
US10/769,018 US20050014848A1 (en) 2002-01-23 2004-01-30 Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
US10/860,721 US20050009927A1 (en) 2002-01-23 2004-06-03 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors

Publications (1)

Publication Number Publication Date
TW200526197A true TW200526197A (en) 2005-08-16

Family

ID=34280166

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093127197A TW200526197A (en) 2003-09-09 2004-09-08 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors

Country Status (7)

Country Link
EP (1) EP1667686A1 (nl)
BR (1) BRPI0413726A (nl)
CA (1) CA2542339A1 (nl)
MX (1) MXPA06002778A (nl)
NL (1) NL1026989C2 (nl)
TW (1) TW200526197A (nl)
WO (1) WO2005023265A1 (nl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723957A3 (en) 2002-12-27 2013-01-23 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1763354A2 (en) * 2004-06-09 2007-03-21 Pfizer Limited Use of reboxetine for the treatment of pain
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES

Also Published As

Publication number Publication date
CA2542339A1 (en) 2005-03-17
EP1667686A1 (en) 2006-06-14
NL1026989C2 (nl) 2006-01-10
MXPA06002778A (es) 2006-06-14
WO2005023265A1 (en) 2005-03-17
NL1026989A1 (nl) 2005-03-10
BRPI0413726A (pt) 2006-11-07

Similar Documents

Publication Publication Date Title
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
US8703823B2 (en) Methods for treatment of migraine and symptoms thereof
TW200427450A (en) Pharmaceutical composition comprising histamine H3 receptor antagonist providing nasal decongestant effect
NZ264774A (en) Use of fluoxetine, venlafaxine, milnacipran and duloxetine with a synergist in pharmaceutical compositions
TW200524582A (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
JP2013529654A (ja) レボカルニチン及びドベシレートを含む医薬組成物
TW200831097A (en) Treatment of anxiety with eszopiclone
EP0759299B1 (en) Potentiation of serotonin response
AU2004311869A1 (en) Compositions and methods to treat recurrent medical conditions
TW200835477A (en) Methods for treating depression
ES2544840T3 (es) Clenbuterol para su uso en el tratamiento del autismo
US20050014848A1 (en) Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
TW200526197A (en) Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
JP2023528884A (ja) 疾患の処置用の２－（ジエチルアミノ）エチル２－（４－イソブチルフェニル）プロピオネートの局所投与
PT1461042E (pt) Utilização de desoxipeganina para o tratamento da depressão clínica
TW200528098A (en) Treatment of insomnia in human patients
JP5376481B1 (ja) 経皮吸収用医薬組成物
AU2018371628B2 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
TW200817003A (en) Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物
WO2024160392A1 (en) 5-meo-dmt for use in the treatment of postpartum depression
Suvar Antidepressants
US20240108601A1 (en) Treatment of mental disorders
WO2023186827A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression